0001104659-23-122840.txt : 20231201 0001104659-23-122840.hdr.sgml : 20231201 20231201161602 ACCESSION NUMBER: 0001104659-23-122840 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mehra Raj CENTRAL INDEX KEY: 0001757892 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 231459723 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 tm2331921-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-12-01 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001757892 Mehra Raj C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 1 1 0 0 See Remarks 0 Common Stock 2023-12-01 4 P 0 75757 1.32 A 185142 D Common Stock Warrant (right to buy) 1.32 2023-12-01 4 P 0 75757 A 2023-12-01 2028-12-01 Common Stock 75757 75757 D Each share of common stock was purchased together with an accompanying warrant to purchase one share of common stock in an underwritten public offering at a combined offering price of $1.32 per share of common stock and accompanying warrant. Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split. President, Chief Executive Officer and Chairman of the Board of Directors /s/ Raj Mehra 2023-12-01